our Research Strategy 2012-2020
Since our foundation in 1996, and through our merger with
Prostate Action, we have awarded over £23 million to innovative
research aimed at extending and improving the lives of men who are
diagnosed with prostate cancer. In 2012 we moved our research
funding to a new level; thanks to the income raised by the Movember
Foundation we will begin committing over £7 million to new research
each year for at least the next three years. Our research
strategy outlines how we think we can best invest this vastly
increased sum to achieve real differences for men affected by
prostate cancer by the year 2020.
Described in our Research
Strategy 2012-20 are three priority research areas and the
funding mechanisms we will use to help accelerate research in these
areas. From 2012-2020 all our research funding is targeted
- identifying men at highest risk of developing aggressive
- better tests to distinguish indolent from aggressive tumours,
- new targeted treatments for advanced prostate cancer.
Our new funding streams emphasise innovation, collaboration,
training and career development.